# US 2026/0062478 A1 · Anti-par-2 antibodies and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062478 A1
- Document ID: US20260062478A1
- Status: Published application
- Kind: A1
- Application number: 19/260,054
- Filed: 2025-07-03
- Published: 2026-03-05
- Earliest claimed: 2020-08-18
- Assignees: Cephalon, Inc.
- Applicants: Cephalon LLC
- Inventors: Anna Mikaela BRACKEN; Adam CLARKE; Bridget A. COOKSEY; Anthony Gerard DOYLE; Mark Terence LIDDAMENT; Matthew POLLARD; Lynn POULTON; Anna Maria Matilda QUIGLEY; Julia ROZENFELD; Marta SZABAT
- Web page: https://patentgrep.com/patent/US20260062478A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/10: Anti-acne agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/04: specific for metastasis
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PAR-2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PAR-2 block the interaction between a PAR-2 activating ligand and an extracellular domain of PAR-2, and/or blocks PAR-2 activation by a PAR-2 activating ligand, In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased expression of PAR-2 and/or diseases or conditions that can be alleviated by antagonizing activation of PAR-2 by a PAR-2 activating ligand (e.g., airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).

## Claims

### Claim at position 1

-61. (canceled)

### Claim 62

A method of treating an inflammatory condition in a patient, the method comprising administering to the patient a therapeutically effective amount of an isolated antibody or antigen binding fragment thereof that specifically binds to human protease activated receptor 2 (PAR-2) and comprises the heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3 and the light chain variable region (VL) CDR1, VL CDR2, and VL CDR3 amino acid sequences of:
(a) SEQ ID NOs: 10, 11, 12, 16, 17, and 18, respectively;
(b) SEQ ID NOs: 7, 8, 9, 13, 14, and 15, respectively;
(c) SEQ ID NOs: 10, 11, 12, 16, 19, and 18, respectively;
(d) SEQ ID NOs: 10, 11, 12, 16, 29, and 18, respectively; or
(e) SEQ ID NOs: 10, 11, 12, 16, 22, and 18, respectively.

### Claim 63 (depends on 62)

The method of claim 62, wherein the inflammatory condition is rheumatoid arthritis, osteoarthritis, inflammation-induced visceral hypersensitivity, periodontal disease, or a pathology associated with acute corona virus infection.

### Claim at position 4

-67. (canceled)

### Claim 68 (depends on 1, 62)

The method of claim 62, wherein the isolated antibody or antigen-binding fragment of claim 1 that comprises the heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3 and light chain variable region (VL) CDR1, VL CDR2, and VL CDR3 sequences of SEQ ID NOs: 10, 11, 12, 16, 17, and 18, respectively.

### Claim 69 (depends on 1, 62)

The method of claim 62, wherein the isolated antibody or antigen-binding fragment of claim 1 that comprises the heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3 and light chain variable region (VL) CDR1, VL CDR2, and VL CDR3 sequences of SEQ ID NOs: 7, 8, 9, 13, 14, and 15, respectively.

### Claim 70 (depends on 1, 62)

The method of claim 62, wherein the isolated antibody or antigen-binding fragment of claim 1 that comprises the heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3 and light chain variable region (VL) CDR1, VL CDR2, and VL CDR3 sequences of SEQ ID NOs: 10, 11, 12, 16, 19, and 18, respectively.

### Claim 71 (depends on 1, 62)

The method of claim 62, wherein the isolated antibody or antigen-binding fragment of claim 1 that comprises the heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3 and light chain variable region (VL) CDR1, VL CDR2, and VL CDR3 sequences of SEQ ID NOs: 10, 11, 12, 16, 29, and 18, respectively.

### Claim 72 (depends on 1, 62)

The method of claim 62, wherein the isolated antibody or antigen-binding fragment of claim 1 that comprises the heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3 and light chain variable region (VL) CDR1, VL CDR2, and VL CDR3 sequences of SEQ ID NOs: 10, 11, 12, 16, 22, and 18, respectively.

### Claim 73 (depends on 62)

The method of claim 62, wherein the isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL) comprising the amino acid sequences of:
(a) SEQ ID NOs: 21 and 24, respectively;
(b) SEQ ID NOs: 20 and 23, respectively;
(c) SEQ ID NOs: 21 and 25, respectively;
(d) SEQ ID NOs: 21 and 26, respectively; or
(e) SEQ ID NOs: 21 and 27, respectively.

### Claim 74 (depends on 73)

The method of claim 73, wherein the isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NOs: 21 and 24, respectively.

### Claim 75 (depends on 73)

The method of claim 73, wherein the isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NOs: 20 and 23, respectively.

### Claim 76 (depends on 73)

The method of claim 73, wherein the isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NOs: 21 and 25, respectively.

### Claim 77 (depends on 73)

The method of claim 73, wherein the isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NOs: 21 and 26, respectively.

### Claim 78 (depends on 73)

The method of claim 73, wherein the isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NOs: 21 and 27, respectively.

### Claim 79 (depends on 62)

The method of claim 62, wherein the isolated antibody or antigen-binding fragment thereof comprises a heavy chain constant region and a light chain constant region.

### Claim 80 (depends on 79)

The method of claim 79, wherein the heavy chain constant region is an isotype selected from the group consisting of human IgG1, IgG2, IgG3, and IgG4 isotypes.

### Claim 81 (depends on 80)

The method of claim 80, wherein the heavy chain constant region is a human IgG4 heavy chain constant region or a human IgG4 heavy chain constant region, which has one or more amino acid substitutions.

### Claim 82 (depends on 81)

The method of claim 81, wherein the human IgG4 heavy chain constant region comprises the S228P substitution (by EU numbering) or terminal lysine deletion (K447Δ) (by EU numbering).

### Claim 83 (depends on 79)

The method of claim 79, wherein the light chain constant region is a human IgGκ light chain constant region.

### Claim 84 (depends on 62)

The method of claim 62, wherein the isolated antibody or antigen-binding fragment thereof has binding affinity (KD) to human PAR-2 from about 4×10−10 M to about 1×10−9 M.

### Claim 85 (depends on 62)

The method of claim 62, wherein the isolated antibody or antigen-binding fragment thereof inhibits interaction between the soluble PAR-2 activating ligand and PAR-2 in a cell with an IC50 from about 0.1 nM to about 17 nM, as measured by a PAR-2 β-arrestin cell assay.
